- Home
- News
-
Immune cell regulation company MiroBio relocates to The Oxford Science Park
Immune cell regulation company MiroBio relocates to The Oxford Science Park
01 July 2020
Oxford, UK, 1 July 2020 – The community of innovative companies at The Oxford Science Park, one of the UK’s leading parks for science and technology companies, is being enhanced by the addition of MiroBio, a novel therapeutics company based on insights into the regulation of receptor signalling in immune cells. MiroBio, which launched in October last year with a £27m Series A round, is taking laboratory and office space at the Park as it expands its drug discovery work. The company’s 15-strong team, most of whom are scientists, is expected to grow further as the company develops.
MiroBio was spun out in 2019 from the laboratories of Simon Davis, Professor of Molecular Immunology at the MRC Weatherall Institute of Molecular Medicine, and Richard Cornall, Nuffield Professor of Clinical Medicine at the University of Oxford. Initially, the company is focusing on auto-immune disease, and is exploring other disease areas opportunistically. It was previously based at the Oxford BioEscalator, where many life sciences start-ups are based when they first spin out from the University.
Piers Scrimshaw-Wright, CEO of The Oxford Science Park, said, ‘MiroBio is a very welcome addition to our innovation community, and we look forward to seeing the company develop further. As a spin-out of the University and a ‘graduate’ of the BioEscalator now taking space at The Oxford Science Park, it is a fine example of Oxford’s ecosystem flourishing.’
–ENDS–
For more information, please contact:
The Oxford Science Park
Emma Palmer Foster, Strategic Communications Consultant
T: +44 (0)7880 787185
emmapf@oxfordsp.com
MiroBio
Dr Eliot Charles, Executive Chairman
comms@mirobio.com
Notes to editors
About The Oxford Science Park
The Oxford Science Park is owned and managed by Magdalen College, Oxford. Created in 1991, the Park upholds the College’s heritage and provides one of the most influential Science & Technology environments in the UK. There is approaching 750,000 square feet of workspace accommodation across the Park, which is now home to more than 2,700 people and more than 130 businesses. These range from start-ups based in the Magdalen Centre innovation hub to major international companies and include: Blue Earth Diagnostics, OrganOx, OxSonics Therapeutics, Oxford Nanopore Technologies, OXGENE, Oxford Sciences Innovation, Evox Therapeutics, Vaccitech, Exscientia, Sensyne Health and Intuitive Surgical.
In addition to being a key property investment, the Park is at the heart of Magdalen College’s strategy to support discovery, innovation and entrepreneurship. It will continue to develop The Oxford Science Park as a long-term strategic asset, with ambitious plans to create an additional 500,000+ sq ft of office and laboratory space on the remaining 12 acres of land over the next 3-5 years. This additional capacity will support the growth of businesses already based on the Park, providing flexible workspace accommodation, and enabling new companies to enjoy the Park’s exceptional environment and collegiate and collaborative ethos. The Oxford Science Park is located approximately four miles south-east of Oxford city centre, just off the City’s southern ring road. It has easy access to the M40 and A34, as well as to Heathrow Airport and mainline train services. For further information, please visit: www.oxfordsp.com or follow us on twitter @OxfordSciencePK
About MiroBio
MiroBio was established as a spin-out from the University of Oxford in 2019. It is developing antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. Its platform is based on the work of its founding scientists, Simon Davis, Professor of Molecular Immunology, MRC Weatherall Institute of Molecular Medicine, and Richard Cornall, Nuffield Professor of Clinical Medicine at the University of Oxford. Their understanding of how immune receptor signalling takes place at the cell surface has generated a platform of IP and technologies which is being exploited by MiroBio.
The company has assembled a team of drug discovery and development experts and is based at The Oxford Science Park. In October 2019 it raised £27m from an international syndicate of life sciences investors including Advent Life Sciences, Oxford Sciences Innovation, Samsara Biocapital and SR One. For more information please go to www.mirobio.com.
Read other news articles